User profiles for Johannes Levin

Johannes Levin

Professor for Clinical Neurodegeneration, Ludwig-Maximilians-Universität München; CMO …
Verified email at med.uni-muenchen.de
Cited by 14429

Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria

…, J Kassubek, F Krismer, J Levin… - Movement …, 2017 - Wiley Online Library
Background: PSP is a neuropathologically defined disease entity. Clinical diagnostic criteria,
published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for …

Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease

…, C LaFougere, C Laske, J Vöglein, J Levin… - Nature medicine, 2019 - nature.com
Neurofilament light chain (NfL) is a promising fluid biomarker of disease progression for
various cerebral proteopathies. Here we leverage the unique characteristics of the Dominantly …

A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease

…, RN Martins, A O'connor, NC Fox, J Levin… - Nature medicine, 2020 - nature.com
Abstract Development of tau-based therapies for Alzheimer’s disease requires an understanding
of the timing of disease-related changes in tau. We quantified the phosphorylation state …

Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study

…, NR Graff-Radford, C la Fougère, J Levin… - The Lancet …, 2018 - thelancet.com
Background Models of Alzheimer's disease propose a sequence of amyloid β (Aβ) accumulation,
hypometabolism, and structural decline that precedes the onset of clinical dementia. …

Hough-CNN: Deep learning for segmentation of deep brain regions in MRI and ultrasound

…, C Kroll, A Plate, V Rozanski, J Maiostre, J Levin… - Computer Vision and …, 2017 - Elsevier
In this work we propose a novel approach to perform segmentation by leveraging the abstraction
capabilities of convolutional neural networks (CNNs). Our method is based on Hough …

[HTML][HTML] Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease

…, PR Schofield, T Ikeuchi, H Mori, J Levin… - Nature medicine, 2023 - nature.com
Alzheimer’s disease (AD) pathology develops many years before the onset of cognitive
symptoms. Two pathological processes—aggregation of the amyloid-β (Aβ) peptide into plaques …

[HTML][HTML] Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease

J Wagner, S Ryazanov, A Leonov, J Levin, S Shi… - Acta …, 2013 - Springer
In neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD)
and prion diseases, deposits of aggregated disease-specific proteins are found. Oligomeric …

Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases

…, K Buerger, R Perneczky, J Levin… - Science translational …, 2021 - science.org
2-Deoxy-2-[ 18 F]fluoro-d-glucose positron emission tomography (FDG-PET) is widely used
to study cerebral glucose metabolism. Here, we investigated whether the FDG-PET signal is …

Anti-amyloid antibody therapies in Alzheimer's disease

R Perneczky, F Jessen, T Grimmer, J Levin, A Flöel… - Brain, 2023 - academic.oup.com
After years of failed attempts to develop a disease-modifying therapy for Alzheimer’s disease,
consistent evidence in support of clinical efficacy was finally presented for a monoclonal …

[HTML][HTML] Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds

M Caruana, T Högen, J Levin, A Hillmer, A Giese… - FEBS letters, 2011 - Elsevier
Aggregation of alpha-synuclein (αS) into oligomers is critically involved in the pathogenesis
of Parkinson’s disease (PD). Using confocal single-molecule fluorescence spectroscopy, we …